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there are two points making the interpretation of the results pre-
sented by Singh et al. difﬁcult: urine sodium concentration
(60.6 ± 22.3 mval/L in patients with terlipressin and 46.9 ±
23.5 mval/L in patients with noradrenaline) was relatively high
in patients with HRS. Sepsis was the main cause of short term
mortality (14/29), therefore ongoing infection cannot be excluded
in some of the patients at the start of vasopressing agents treat-
ment. Unresolved infections would have had a major inﬂuence on
changes in renal function and prognosis.
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JOURNAL OF HEPATOLOGYTo the Editor:
In a randomized study, Singh et al. evaluated the efﬁcacy of nor-
adrenaline vs. terlipressin in the treatment of patients with HRS1
[1]. According to their results, they suggest that noradrenaline is
as safe and effective as terlipressin, but less expensive. The
response of noradrenaline is mostly due to its vasoconstricting a-
mimetic and perhaps additional ß-mimetic effects. The ﬁrst report
on a vasopressor therapy in a patient with renal dysfunction was
published ﬁfty years ago [2]. Metaraminol, an a- and ß-mimetic
substance, increased the excretion of water, sodium, and potas-
sium, as well as the inulin and PAH clearance in cirrhotic patients
with and without renal insufﬁciency. The following studies
showedconﬂicting results [3] andvasopressors havenot beenused
since the late 1980s. Vasopressor therapy at that time was started
with vasopressin derivates like ornipressin and later terlipressin.
The ideaof usingornipressin came fromthe fact that noradrenaline
was not available any more in the mid 1980s. Recently, in placebo
controlled studies with terlipressin and albumin, an increase in
renal function in patients with HRS compared to albumin alone
could be observed in about 40% of the patients. This combination
is now recommended for the treatment of patients with HRS [4].
In the last years, pilot studies using again noradrenaline
showed an increase in renal function of patients with HRS. In a
randomized study, Singh et al. found that noradrenaline was as
effective as the ‘‘standard therapy’’ terlipressin. Has the time
come to switch from terlipressin to noradrenaline? Arguments
for using noradrenaline are costs, and the positive inotropic effect
of noradrenaline, since cardiac insufﬁciency may be one cause of
deteriorating renal function in cirrhosis [5,6]. Toward the use of
noradrenaline is the necessity of a central venous catheter for
noradrenaline infusion, because of the problem of bolus injection
if using a peripheral venous catheter. On the other hand, one of
the factors leading to renal hypoperfusion in advanced portal
decompensation is loss of renal autoregulation [7]. In experimen-
tal data, a resetting of autoregulation could be induced by vaso-
pressin [8], therefore terlipressin should be favoured. The
relevance of the loss of autoregulation has been shown in many
studies; as well as in the study of Singh et al., as mean arterial
pressure was associated with response. Therefore, therapy should
be primarily guided by the effect on arterial pressure, which was
only done in this study, in the noradrenaline treated patients, but
not in the terlipressin treated patients. Further studies comparing
these substances should therefore use blood pressure for guiding
the doses of the vasopressors used, as well as with terlipressin.
This could be problematic in the case of bolus injections of terli-
pressin. Terlipressin has been shown, in a small retrospective
study [9] and a pilot study [10], to be as effective when given
as continuous infusion; a comparison of continuous infusion of
terlipressin with noradrenaline, in a dose guided by mean arterial
pressure, may be a better way to give a correct answer for a dif-
ference in the effectiveness of these two vasopressors. At leastJournal of Hepatology 2012 vol. 57 j 921–934 925
